Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
The SERENA-6 study reveals that ESR1 mutations, a key resistance mechanism, emerge steadily throughout first-line aromatase inhibitor and CDK4/6 inhibitor therapy. This finding indicates that a single ctDNA test is inadequate. Instead, a strategy of continuous, serial monitoring is necessary to detect molecular relapse in real-time, posing a new paradigm for patient management.
Related Insights
The SERENA-6 trial showed improved survival by switching therapy upon ctDNA detection of ESR1 mutations. However, it required screening over 3,300 patients to randomize just 315, highlighting the immense scale, cost, and patient drop-off of applying this serial monitoring strategy in standard clinical practice.
ESR1 mutations are rarely found in primary tumors but develop in metastatic settings under pressure from aromatase inhibitors, conferring resistance. This evolution necessitates serial, plasma-based genotyping upon each disease progression to identify these actionable mutations as they emerge.
ESR1 mutations in breast cancer are acquired alterations, meaning they can be missed by a single test. The speaker advocates for serial testing, especially after disease progression, using blood-based ctDNA analysis. This dynamic monitoring approach is essential for identifying patients who become eligible for targeted therapies over time.
Dr. Bardia emphasizes that ESR1 is an 'acquired alteration,' meaning the mutation can develop during treatment. This necessitates a shift from one-time diagnostic testing to a dynamic, serial testing model. Repeat testing is critical to identify these actionable mutations as they arise, allowing patients to access newly approved targeted therapies.
The SERINA-6 trial suggests a paradigm shift: proactively switching from an AI to an oral SERD upon detecting an ESR1 mutation in ctDNA—before clinical or radiographic progression—significantly improves progression-free survival and patient quality of life.
SERENNA-six pioneers a strategy where treatment is switched upon detecting an ESR1 resistance mutation in ctDNA, *before* the patient shows clinical signs of progression. This proactive, biomarker-driven approach represents a paradigm shift from reactive treatment of progressing disease.
Despite the promise of liquid biopsies for monitoring, the SERENA-6 trial revealed a significant challenge: fewer than 10% of screened patients developed a detectable ESR1 mutation. This low yield questions the efficiency and broad applicability of this serial screening strategy to guide treatment changes.
The SERINA-6 trial supports a paradigm shift: proactively screening for ESR1 mutations via blood test and switching to camisestrant upon detection, even without radiological progression. This early switch based on molecular signals nearly doubled median progression-free survival from 9 to 16 months.
The SERENA-6 trial tested a hypothesis rooted in evolutionary biology: intervening when a resistance mutation (ESR1) first appears in ctDNA, while the clone is small and less diverse, rather than waiting for clinical progression. This proactive approach aims to control resistance before it becomes dominant and harder to treat.
The trial showed a profound 100% median reduction in ESR1 mutation frequency in the camisestrant arm versus a 66% increase in the control arm. This provides a powerful pharmacodynamic signal that the drug is potently inhibiting its intended target—the mutated estrogen receptor—and offers a clear molecular rationale for its clinical efficacy.